IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials
IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Advantages of IgY over other antibodies comprise its cost-effective extraction, the minimization of animal harm and distress, and its reduced reactivity with mammalian factors. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. This review provides a comprehensive analysis of IgY-based biologicals for human medicine, including patent applications and clinical trials during the period 2010–2018, and addresses how IgY-technology can lead to innovation in the production of biologicals for the treatment and prophylaxis of a wide range of infectious and non-communicable diseases.
Main Authors: | , , , , |
---|---|
Format: | info:ar-repo/semantics/artículo biblioteca |
Language: | eng |
Published: |
Elsevier
2020-04
|
Subjects: | Antibodies, Egg Yolk, Therapy, Patents, Clinical Trials, Medical Sciences, Human Diseases, Anticuerpos, Yema de Huevo, Terapia, Patentes, Ensayos Clínicos, Ciencias Médicas, Enfermedades Humanas, IgY Antibody, Anticuerpo IgY, |
Online Access: | http://hdl.handle.net/20.500.12123/6713 https://www.sciencedirect.com/science/article/pii/S1567576919323677 https://doi.org/10.1016/j.intimp.2020.106269 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:localhost:20.500.12123-6713 |
---|---|
record_format |
koha |
spelling |
oai:localhost:20.500.12123-67132023-01-13T13:59:26Z IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials Leiva, Carlos Gallardo, Mauro Julián Casanova, Natalia Andrea Terzolo, Horacio Chacana, Pablo Antibodies Egg Yolk Therapy Patents Clinical Trials Medical Sciences Human Diseases Anticuerpos Yema de Huevo Terapia Patentes Ensayos Clínicos Ciencias Médicas Enfermedades Humanas IgY Antibody Anticuerpo IgY IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Advantages of IgY over other antibodies comprise its cost-effective extraction, the minimization of animal harm and distress, and its reduced reactivity with mammalian factors. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. This review provides a comprehensive analysis of IgY-based biologicals for human medicine, including patent applications and clinical trials during the period 2010–2018, and addresses how IgY-technology can lead to innovation in the production of biologicals for the treatment and prophylaxis of a wide range of infectious and non-communicable diseases. Instituto de Patobiología Fil: Leiva, Carlos. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gallardo, Mauro Julián. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Casanova, Natalia Andrea. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Terzolo, Horacio. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: Chacana, Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina 2020-02-11T11:10:19Z 2020-02-11T11:10:19Z 2020-04 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/6713 https://www.sciencedirect.com/science/article/pii/S1567576919323677 1567-5769 https://doi.org/10.1016/j.intimp.2020.106269 eng info:eu-repo/semantics/restrictedAccess application/pdf Elsevier International Immunopharmacology 81 : 106269 (Abril 2020) |
institution |
INTA AR |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-inta-ar |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Biblioteca Central del INTA Argentina |
language |
eng |
topic |
Antibodies Egg Yolk Therapy Patents Clinical Trials Medical Sciences Human Diseases Anticuerpos Yema de Huevo Terapia Patentes Ensayos Clínicos Ciencias Médicas Enfermedades Humanas IgY Antibody Anticuerpo IgY Antibodies Egg Yolk Therapy Patents Clinical Trials Medical Sciences Human Diseases Anticuerpos Yema de Huevo Terapia Patentes Ensayos Clínicos Ciencias Médicas Enfermedades Humanas IgY Antibody Anticuerpo IgY |
spellingShingle |
Antibodies Egg Yolk Therapy Patents Clinical Trials Medical Sciences Human Diseases Anticuerpos Yema de Huevo Terapia Patentes Ensayos Clínicos Ciencias Médicas Enfermedades Humanas IgY Antibody Anticuerpo IgY Antibodies Egg Yolk Therapy Patents Clinical Trials Medical Sciences Human Diseases Anticuerpos Yema de Huevo Terapia Patentes Ensayos Clínicos Ciencias Médicas Enfermedades Humanas IgY Antibody Anticuerpo IgY Leiva, Carlos Gallardo, Mauro Julián Casanova, Natalia Andrea Terzolo, Horacio Chacana, Pablo IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
description |
IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Advantages of IgY over other antibodies comprise its cost-effective extraction, the minimization of animal harm and distress, and its reduced reactivity with mammalian factors. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. This review provides a comprehensive analysis of IgY-based biologicals for human medicine, including patent applications and clinical trials during the period 2010–2018, and addresses how IgY-technology can lead to innovation in the production of biologicals for the treatment and prophylaxis of a wide range of infectious and non-communicable diseases. |
format |
info:ar-repo/semantics/artículo |
topic_facet |
Antibodies Egg Yolk Therapy Patents Clinical Trials Medical Sciences Human Diseases Anticuerpos Yema de Huevo Terapia Patentes Ensayos Clínicos Ciencias Médicas Enfermedades Humanas IgY Antibody Anticuerpo IgY |
author |
Leiva, Carlos Gallardo, Mauro Julián Casanova, Natalia Andrea Terzolo, Horacio Chacana, Pablo |
author_facet |
Leiva, Carlos Gallardo, Mauro Julián Casanova, Natalia Andrea Terzolo, Horacio Chacana, Pablo |
author_sort |
Leiva, Carlos |
title |
IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
title_short |
IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
title_full |
IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
title_fullStr |
IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
title_full_unstemmed |
IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
title_sort |
igy-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials |
publisher |
Elsevier |
publishDate |
2020-04 |
url |
http://hdl.handle.net/20.500.12123/6713 https://www.sciencedirect.com/science/article/pii/S1567576919323677 https://doi.org/10.1016/j.intimp.2020.106269 |
work_keys_str_mv |
AT leivacarlos igytechnologyeggyolkantibodiesinhumanmedicineareviewofpatentsandclinicaltrials AT gallardomaurojulian igytechnologyeggyolkantibodiesinhumanmedicineareviewofpatentsandclinicaltrials AT casanovanataliaandrea igytechnologyeggyolkantibodiesinhumanmedicineareviewofpatentsandclinicaltrials AT terzolohoracio igytechnologyeggyolkantibodiesinhumanmedicineareviewofpatentsandclinicaltrials AT chacanapablo igytechnologyeggyolkantibodiesinhumanmedicineareviewofpatentsandclinicaltrials |
_version_ |
1762927283547406336 |